在CRSwNP中延长Dupilumab的剂量间隔:五年的现实世界结果
Nicholas J Campion1, Dioni-Pinelopi Petsiou1, Florian C Fally1
1Vienna Airway Lab, Department of Otorhinolaryngology, General Hospital and Medical University of Vienna, Vienna, Austria.
International forum of allergy & rhinology
|March 2, 2026
概括
长期的dupilumab治疗有效地控制了带有鼻息肉的慢性鼻炎 (CRSwNP),延长了剂量间隔,保持了疗效并提高了安全性. 这种方法为CRSwNP治疗提供了个性化的策略.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
背景情况:
- 带鼻息肉的慢性鼻炎 (CRSwNP) 是一种使人虚弱的2型炎症状况,影响生活质量.
- 杜皮卢马布可以快速缓解症状,但长期疗效和延长剂量间隔的影响需要进一步研究.
研究的目的:
- 评估dupilumab在CRSwNP患者的长期实际结果.
- 评估在疾病控制后延长dupilumab剂量间隔的有效性和安全性.
主要方法:
- 对224名成年CRSwNP患者的回顾性分析,这些患者接受多皮卢马布治疗长达4.5年.
- 长度评估多体大小,症状,嗅觉,喘控制和2型生物标志物.
- 标准2周剂量与延长剂量间隔之间的结果比较.
主要成果:
- 杜皮卢马布在5年内显示出对多体负担,嗅觉和生活质量持续改善.
- 40%的患者延长了剂量间隔,没有失效,并且报告了较少的不良事件.
- 总体而言,副作用发生率为16%,主要是肌肉骨疾病,皮肤和注射部位反应.
结论:
- 长期的杜皮卢马布治疗确保了CRSwNP的持久的疾病控制和安全.
- 个性化延长dupilumab剂量间隔保持有效性,同时减少治疗负担.
- 延长剂量可以优化长期CRSwNP管理,特别是对于出现副作用的患者.
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
958
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
958
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
344
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
344
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
301
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
301
Drugs Used in Lower Respiratory Disorders: Overview
1.3K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.3K
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
58
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
58
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
68
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
68


